{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:03:06Z","timestamp":1781128986694,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clcc.2026.03.002","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:00:56Z","timestamp":1773676856000},"page":"283-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and Risk Factors of Non-neutropenic Enterocolitis With Adjuvant Capecitabine and Oxaliplatin Chemotherapy in Colorectal Cancer"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5501-1036","authenticated-orcid":false,"given":"Guillaume","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakan","family":"Okde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Cull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0799-1551","authenticated-orcid":false,"given":"M\u00e9lina","family":"Boutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.clcc.2026.03.002_bib0001","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clcc.2026.03.002_bib0002","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2006.08.1075","article-title":"Phase III trial of Capecitabine plus Oxaliplatin As adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients","volume":"25","author":"Schmoll","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clcc.2026.03.002_bib0003","first-page":"172","article-title":"CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer","volume":"13","author":"Loree","year":"2014","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2026.03.002_bib0004","article-title":"Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil\/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.03.002_bib0005","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2007.15.2090","article-title":"Potential regional differences for the tolerability profiles of fluoropyrimidines","author":"Haller","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.03.002_bib0006","first-page":"370","article-title":"members of the AJCC Precision Medicine Core. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine","volume":"66","author":"Kattan","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2026.03.002_bib0007","series-title":"Principles of Biostatistics","author":"Pagano","year":"2018"},{"issue":"2","key":"10.1016\/j.clcc.2026.03.002_bib0008","first-page":"156","article-title":"Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer","volume":"17","author":"Loree","year":"2018","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.clcc.2026.03.002_bib0009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/gidisord4030020","article-title":"Retrospective analysis of the safety of FOLFOX compared to CAPOX for adjuvant treatment of stage III colorectal cancer in Newfoundland patients","volume":"4","author":"McShane","year":"2022","journal-title":"Gastrointest Disord"},{"issue":"1","key":"10.1016\/j.clcc.2026.03.002_bib0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.bjc.6605995","article-title":"Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction","volume":"104","author":"Baird","year":"2011","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.clcc.2026.03.002_bib0011","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2026.03.002_bib0012","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/annonc\/mdn370","article-title":"Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil\/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study","volume":"19","author":"Rothenberg","year":"2008","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clcc.2026.03.002_bib0013","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-017-3419-1","article-title":"Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer","volume":"80","author":"Danno","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.clcc.2026.03.002_bib0014","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/ijc.IJC_618_19","article-title":"Efficacy and safety of capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer: an observational study from a tertiary cancer center in South India","volume":"59","author":"Kalidindi","year":"2022","journal-title":"Indian J Cancer"},{"issue":"11","key":"10.1016\/j.clcc.2026.03.002_bib0015","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.7314\/APJCP.2013.14.11.6585","article-title":"Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis","volume":"14","author":"Chiu","year":"2023","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"10.1016\/j.clcc.2026.03.002_bib0016","first-page":"1741","article-title":"A feasibility study of capecitabine and oxaliplatin for patients with stage II\/III colon cancer \u2013 ACTOR study","volume":"38","author":"Suenaga","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clcc.2026.03.002_bib0017","doi-asserted-by":"crossref","unstructured":"Berretta M, Aprile G, Nasti G, et al. Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients. Anticancer Agents Med Chem. 13(9):1344-1353. doi:10.2174\/18715206113136660347","DOI":"10.2174\/18715206113136660347"},{"issue":"3","key":"10.1016\/j.clcc.2026.03.002_bib0018","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ijc.25369","article-title":"Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil\/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer","volume":"128","author":"Ducreux","year":"2011","journal-title":"Int J Cancer"},{"issue":"27","key":"10.1016\/j.clcc.2026.03.002_bib0019","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2006.09.2684","article-title":"Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO colorectal study group","volume":"25","author":"Porschen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.clcc.2026.03.002_bib0020","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1200\/JCO.2006.09.8467","volume":"25","author":"D\u00edaz-Rubio","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.03.002_bib0021","article-title":"Risk factor of severe diarrhea and enterocolitis induced by CAPOX: a retrospective multicenter study","volume":"6","author":"Teixeira","year":"2024","journal-title":"ESMO Gastrointest Oncol"},{"key":"10.1016\/j.clcc.2026.03.002_bib0022","first-page":"1014","article-title":"Clinical factors related to severe enterocolitis after adjuvant CAPOX for colorectal cancer: a retrospective analysis","volume":"14","author":"Felismino","year":"2020","journal-title":"ECancer"},{"issue":"1","key":"10.1016\/j.clcc.2026.03.002_bib0023","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12957-021-02443-8","article-title":"Severe ileum bleeding following adjuvant capecitabine chemotherapy for locally advanced colon cancer: a case report and review of the literature","volume":"19","author":"Zou","year":"2021","journal-title":"World J Surg Oncol"},{"issue":"6","key":"10.1016\/j.clcc.2026.03.002_bib0024","doi-asserted-by":"crossref","first-page":"661","DOI":"10.5144\/0256-4947.2012.661","article-title":"Capecitabine-induced terminal ileitis","volume":"32","author":"Al-Gahmi","year":"2012","journal-title":"Ann Saudi Med"},{"issue":"3","key":"10.1016\/j.clcc.2026.03.002_bib0025","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1159\/000492781","article-title":"Capecitabine-associated terminal ileitis","volume":"11","author":"van Hellemond","year":"2018","journal-title":"Case Rep Oncol"},{"issue":"5","key":"10.1016\/j.clcc.2026.03.002_bib0026","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4253\/wjge.v11.i5.383","article-title":"Role of colonoscopy in diagnosis of capecitabine associated ileitis: two case reports","volume":"11","author":"Dao","year":"2019","journal-title":"World J Gastrointest Endosc"},{"key":"10.1016\/j.clcc.2026.03.002_bib0027","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-203647","article-title":"Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature","volume":"2014","author":"Mokrim","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.clcc.2026.03.002_bib0028","article-title":"Ileitis secondary to oral capecitabine treatment?","volume":"2012","author":"Radwan","year":"2012","journal-title":"Case Rep Med"},{"issue":"6","key":"10.1016\/j.clcc.2026.03.002_bib0029","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3892\/mco.2015.635","article-title":"Severe ileitis associated with capecitabine: two case reports and review of the literature","volume":"3","author":"Lee","year":"2015","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"10.1016\/j.clcc.2026.03.002_bib0030","article-title":"Capecitabine-induced terminal ileitis: case report and literature review","volume":"13","author":"Klimko","year":"2021","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.clcc.2026.03.002_bib0031","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.prp.2014.05.005","article-title":"Capecitabine induced colitis","volume":"210","author":"Maggo","year":"2014","journal-title":"Pathol - Res Pract"},{"issue":"4","key":"10.1016\/j.clcc.2026.03.002_bib0032","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s002800050583","article-title":"Gastric mucosal blood flow and gastric secretion following intravenous administration of 5-fluorouracil in anesthetized rats","volume":"39","author":"Kakinuma","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.clcc.2026.03.002_bib0033","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cyto.2012.10.003","article-title":"Inflammatory intestinal damage induced by 5-fluorouracil requires IL-4","volume":"61","author":"Soares","year":"2013","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.clcc.2026.03.002_bib0034","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/cncr.23013","article-title":"Severe enteropathy among patients with stage II\/III colon cancer treated on a randomized trial of bolus 5-fluorouracil\/leucovorin plus or minus oxaliplatin","volume":"110","author":"Philip Kuebler","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clcc.2026.03.002_bib0035","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ajpa.21424","article-title":"Admixed ancestry and stratification of Quebec regional populations","volume":"144","author":"Bherer","year":"2011","journal-title":"Am J Phys Anthropol"},{"issue":"4","key":"10.1016\/j.clcc.2026.03.002_bib0036","first-page":"283","article-title":"Validaci\u00f3n de polimorfismos gen\u00e9ticos asociados a toxicidad al tratamiento quimioter\u00e1pico en pacientes de cancer colorrectal","volume":"38","author":"Cortejoso","year":"2014","journal-title":"Farm Hosp"},{"issue":"19","key":"10.1016\/j.clcc.2026.03.002_bib0037","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.23.01326","article-title":"Oxaliplatin-based adjuvant chemotherapy in older patients with stage III colon cancer: an ACCENT\/IDEA pooled analysis of 12 trials","volume":"42","author":"Gallois","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300282600023X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300282600023X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T21:53:10Z","timestamp":1781128390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153300282600023X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S153300282600023X"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2026.03.002","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence and Risk Factors of Non-neutropenic Enterocolitis With Adjuvant Capecitabine and Oxaliplatin Chemotherapy in Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2026.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}